

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Upadacitinib for treating giant cell arteritis [ID6299]

Final Stakeholder List

Duradaianal Canaultasa Duradaianal Canaucantatana (n. 1911)	
Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	
Company	General
AbbVie (upadacitinib)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	 Allied Health Professionals Federation
Cardiovascular Care PartnershipCirculation Foundation	 Board of Community Health Councils in Wales
Fight for Sight	British National Formulary
Heart UK	Care Quality Commission
 Pumping Marvellous Foundation 	Department of Health – Northern Ireland
DMDCCA LUC (D. L	Healthcare Improvement Scotland
PMRGCA UK (Polymyalgia Rheumatica & Giant Cell Arteritis UK)	·
,	medianies and mediane products
RAIRDA (The Rare Autoimmune Rhoumatic Disease Alliance)	Regulatory Agency
Rheumatic Disease Alliance)	National Association of Primary Care
Royal National Institute of Blind Page 14 Page 14 Republication of Blind Republication of Bli	National Pharmacy Association
People	NHS Confederation
Somerville Foundation	NHS Wales Joint Commissioning
South Asian Health Foundation	Committee
Specialised Healthcare Alliance	Scottish Medicines Consortium
Vasculitis UK	Welsh Government
Versus Arthritis	
	Comparator companies
Healthcare professional groups	Fresenius Kabi (tocilizumab)
 British Association for Nursing in 	Roche (tocilizumab)
Cardiovascular Care	
British Cardiovascular Intervention	Relevant research groups
Society	British Society for Cardiovascular
British Cardiovascular Society	Research
British Geriatrics Society	Cochrane Heart Group
British Society for Rheumatology	Genomics England
British Society of Cardiovascular	Heart Research UK
Imaging	MRC Clinical Trials Unit
Primary Care Cardiovascular Society	National Centre for Cardiovascular
Primary Care Rheumatology and	Preventions and Outcomes
Muscoloskeletal Medicine Society	National Heart and Lung Institute
Royal College of General Practitioners	National Institute for Health Research
De al Callera (Marchaela)	
, ,	The Society for Research in Rehabilitation
Royal College of Ophthalmologists Royal College of Pothalmologists	Renabilitation
Royal College of Pathologists	

Final stakeholder list for the evaluation of upadacitinib for treating giant cell arteritis [ID6299] Issue date: May 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society of Vascular Nurses UK Clinical Pharmacy Association Vascular Society of Great Britain and Ireland 	 UKIVas (UK and Ireland Vasculitis Rare Disease Group) Wellcome Trust Associated Public Health groups Public Health Wales UK Health Security Agency
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Final stakeholder list for the evaluation of upadacitinib for treating giant cell arteritis [ID6299] Issue date: May 2025